Needham initiated coverage of Dice Therapeutics with a Buy rating and $56 price target. Dice is a clinical-stage biotech developing oral therapeutics against "well-validated" immunology targets with the goal of delivering comparable efficacy to commercially established biologics for various immune-related diseases, the analyst tells investors in a research note. The firm believes Dice offers a "rare pure-play opportunity" to invest in an area of significant takeover interest for large pharma.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DICE:
- Dice Therapeutics discloses $14.8M purchase of common stock by Ra Capital
- This Major Insider is Loading Up on Dice (NASDAQ:DICE) Stock
- DICE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
- Cantor biopharma/biotech analysts hold analyst/industry conference call
- Dice Therapeutics reports Q4 EPS (51c), consensus (49c)
